Alumis Inc.

Status: Publicly traded

Direct answer

Alumis Inc. is publicly traded on NASDAQ under the ticker ALMS.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory...

Can you invest in Alumis Inc.?

Yes. Alumis Inc. is publicly traded on NASDAQ under the ticker ALMS.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Alumis Inc.

Detailed equity research is provided by MarketSnap.